MAPT and Alzheimer disease: These monoclonal antibodies have been designed based on the amyloid hypothesis, wherein AD follows a canonical cascade, with the accumulation of Aβ being the primary event accelerating tau accumulation and spread from the entorhinal cortex (EC) into the neocortex leading to cognitive decline 3.